{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-006942","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.598745+00:00","generated_at":"2026-05-16T02:32:56.698322+00:00","sec_items":["3.02","5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cingulate closes $12M PIPE financing, appoints Jeff Hargroves to board and converts debt","bullets":["Cingulate completed $12M private placement led by Falcon Creek Capital at $5.04 per share with 80% warrant coverage","Jeff Hargroves appointed as Class I director and to Audit, Compensation, and Nominating committees","Company issued 25,786 shares at $6.16 per share to a lender in exchange for debt under Section 3(a)(9)","All PIPE investors subject to 180-day lock-up; total potential proceeds up to $21.4 million","FDA PDUFA target date for CTx-1301 ADHD treatment set for May 31, 2026"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-006942","json":"https://secwatch.observer/filing/0001493152-26-006942.json","markdown":"https://secwatch.observer/filing/0001493152-26-006942.md","text":"https://secwatch.observer/filing/0001493152-26-006942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226006942/0001493152-26-006942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226006942/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T02:32:56.698322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8e258946c5926dbae350766a72082b870ba8000c","claim":"Cingulate Inc. issued 25,786 shares of common stock to a lender for in exchange for a portion of the debt owed.","evidence_excerpt":"On February 6, 2026, Cingulate Inc. (the “ Company ”) issued 25,786 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), at a value of $6.16 per share to a lender in exchange for a portion of the debt owed to such lender.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226006942/0001493152-26-006942-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"25,786 shares"},{"label":"Purchaser","value":"a lender"},{"label":"Consideration","value":"in exchange for a portion of the debt owed"}],"fact_type":"equity_issuance"},{"claim_id":"f1c9814173fe9c5aed462022c212333bfb1387b7","claim":"Cingulate Inc. issued units consisting of convertible preferred stock and warrants of unit to certain affiliates of Falcon Creek Capital Advisor LLC and other institutional investors for $12 million gross proceeds.","evidence_excerpt":"Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules KANSAS CITY, Kan., February 17, 2026 — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by certain affiliates of Falcon Creek Capital Advisor LLC (“Falcon Creek Capital”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226006942/0001493152-26-006942-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"unit"},{"label":"Shares","value":"units consisting of convertible preferred stock and warrants"},{"label":"Purchaser","value":"certain affiliates of Falcon Creek Capital Advisor LLC and other institutional investors"},{"label":"Consideration","value":"$12 million gross proceeds"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}